*Five Years Citation in Google scholar (2016 - 2020) is. 1451*   *    IJPR IS INDEXED IN ELSEVIER EMBASE & EBSCO *       

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence
Published by : Advanced Scientific Research
ISSN
0975-2366
Current Issue
Article In Press
No Data found.
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
Burden of Liver Cancer Attributable to Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Infection in Indonesia

Author: AGATHA LOSITA CANDRADEWI PERTIWI, SUSI ARI KRISTINA
Abstract: Background: Liver cancer is the fifth most common cancer in the world and the third leading cause of cancer-related deaths. Several risk factors for the development of liver cancer have been identified; in these diseases, although their relative contributions show important geographic differences, chronic infections of hepatitis B and C viruses (HBV and HCV) dominate. GLOBOCAN 2018 outlines the morbidity and mortality of 36 cancers (including liver cancer) in many countries, including Indonesia. The purpose of this study is to estimate the morbidity and cost of premature mortality from liver cancer caused by HBV and HCV infection in Indonesia based on the 2018 GLOBOCAN data. Methods: This study used morbidity rate and premature mortality cost to measure the burden of liver cancer caused by infectious agents (HBV and HCV) in Indonesia in 2018. The original data comes from GLOBOCAN 2018. Indonesia's life expectancy was taken from World Health Organization data, and average income from World Development Indicators. Results: The total morbidity of liver cancer due to HBV in Indonesia in 2018 was 3.29% for male and 1.99% for female. The morbidity of liver cancer from HCV infection in male was 0.38% and 0.23% in female. The total cost of premature mortality from liver cancer caused by HBV for male was US$ 69.93 million and US$ 19.97 million for female. The total cost of premature mortality of HCV, which causes liver cancer for male was US$ 8.08 million, and US$ 2.31 million for female group. Conclusion: Using morbidity and premature mortality cost parameters to estimate the burden of liver cancer attributable to HBV and HCV will help the government determine health plans and reduce the prevalence and mortality of this disease in Indonesia.
Keyword: liver cancer, morbidity, premature mortality cost, Indonesia
DOI: https://doi.org/10.31838/ijpr/2021.13.03.161
Download: Request For Article
 




ONLINE SUBMISSION
USER LOGIN
Username
Password
Login | Register
News & Events
SCImago Journal & Country Rank

Terms and Conditions
Disclaimer
Refund Policy
Instrucations for Subscribers
Privacy Policy

Copyrights Form

0.12
2018CiteScore
 
8th percentile
Powered by  Scopus
Google Scholar

hit counters free